In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Boston Scientific wins $27bn bid for Guidant

Executive Summary

In an effort to top rival Johnson & Johnson's recent $21.5bn offer, Boston Scientific Corp. has made its own cash and stock bid for Guidant. BSC has proposed $72 per share ($36 in cash and $36 in stock) for each Guidant outstanding share, valuing the deal at about $25bn, a 14% premium to J&J's offer. J&J bid $76 per share for the company a year ago and has revised its offer several times, the latest being $63.43 per share.

Deal Industry
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash for Equity
    • Payment Includes Stock

Related Companies